RxDoctor Payments Data

Kathleen Morris

Family · Philadelphia, PANPI 1851806442

Payments from drug & device makers

$751in general payments, 2019–2025

Across 22 payments — averaging $34.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$325
  • AstraZeneca$145
  • Johnson & Johnson$104
  • Exact Sciences$61
  • Lilly USA, LLC$26
  • Abbott$23
  • plus $67 from 4 others

What the payments were for

  • Food & beverage$751100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$751 in reported general payments places this provider in the 65th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$38,684
Medicare patients
146
Services billed
565

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide53$49,015
EliquisApixaban50$48,305
JardianceEmpagliflozin35$36,702
JanuviaSitagliptin Phosphate15$18,649
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$9,943
Breo ElliptaFluticasone/Vilanterol22$8,285
Atorvastatin Calcium322$4,251
Albuterol Sulfate HfaAlbuterol Sulfate95$2,381
Levothyroxine Sodium191$2,059
Metformin Hcl ErMetformin Hcl74$1,894
Amlodipine-AtorvastatinAmlodipine/Atorvastatin13$1,751
Metoprolol Succinate101$1,643
Rosuvastatin Calcium79$1,476
Lisinopril181$1,463
Simvastatin122$1,437

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$325$49,01553 claims
MerckJanuvia$19$18,64915 claims
AstraZenecaBreztri Aerosphere$145$9,94312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,717 family providers in Pennsylvania.

Other family in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →